arrow
W

Wenjun Huang

seattle children's therapeutics
H指数:17
被引数:1,201

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Intracerebroventricular B7-H3-targeting chimeric antigen receptor T cells for non-pontine diffuse midline glioma and recurrent/refractory pediatric CNS tumors: A phase 1 trial

脑室内B7-H3靶向嵌合抗原受体T细胞治疗非脑桥弥漫性中线胶质瘤和复发/难治性儿童中枢神经系统肿瘤:一项1期临床试验

2026-07-250
PRE
PIONEERING QUAD-TARGETING CAR T CELL THERAPY IN PEDIATRIC CNS TUMORS - ANALYSIS FROM THE FIRST-IN-HUMAN PHASE 1 TRIAL BRAINCHILD-04

开创性四靶点CAR T细胞疗法在儿童中枢神经系统肿瘤中的应用——来自第一项人体I期临床试验BRAINCHILD-04的分析

2025-11-010
OAAI
Outcomes of PLAT-02 and PLAT-03: evaluating CD19 CAR T-cell therapy and CD19-expressing T-APC support in pediatric B-ALL

PLAT-02和PLAT-03的研究结果:评估CD19 CAR T细胞疗法及CD19表达T-APC支持在儿童B-ALL中的应用

Blood
IF23.1
2025-04-170
PRE
PIONEERING QUAD-TARGETING CAR T CELL THERAPY IN PEDIATRIC CNS TUMORS - ANALYSIS FROM THE INITIAL PATIENTS TREATED ON THE FIRST-IN-HUMAN PHASE 1 TRIAL BRAINCHILD-04
2024-11-110
PRE
PIONEERING QUAD-TARGETING CAR T CELL THERAPY IN PEDIATRIC CNS TUMORS - ANALYSIS FROM THE INITIAL PATIENTS TREATED ON THE FIRST-IN-HUMAN PHASE 1 TRIAL BRAINCHILD-04
2024-06-181
OAAI
Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety

脑室内B7-H3 CAR T细胞用于弥漫性内源性脑桥胶质瘤: 初步的人类首次生物活性和安全性

2022-10-19120
OAAI
Hematopoietic Cell Transplantation after CD19 Chimeric Antigen Receptor T Cell-Induced Acute Lymphoblastic Leukemia Remission Confers a Leukemia-Free Survival Advantage

CD19嵌合抗原受体T细胞诱导的急性淋巴细胞白血病缓解后的造血细胞移植赋予无白血病生存优势

2022-01-0143
OAAI
Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis

在患有复发性或难治性CNS肿瘤的儿童和年轻人中局部区域输注HER2-specific CAR T细胞: 一项中期分析

2021-07-12189
PREAI